If you or someone you know has taken Reglan (metoclopramide) and developed involuntary muscle movements, you may be concerned about tardive dyskinesia. This condition is a known risk with long-term use, and healthcare providers frame it as a serious adverse effect requiring careful monitoring. The following information draws on established medical guidelines to help you understand the clinical perspective and what the science says about risk factors and management.
Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux (4 to 12 weeks) and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. The condition can be disfiguring and may persist after the drug is discontinued. Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves chronic dopamine receptor blockade in the basal ganglia, leading to upregulation and supersensitivity of dopamine receptors, which is thought to contribute to the abnormal involuntary movements.
For patients in New York who have developed TD after using Reglan, the statute of limitations is a critical legal consideration. In New York, personal injury claims generally must be filed within three years of the date the injury was discovered or should have been discovered with reasonable diligence. For medical malpractice claims, the statute of limitations is typically two and a half years from the date of the alleged malpractice or from the end of continuous treatment. However, the specific timeline can vary based on the facts of the case, including when the patient first noticed symptoms of TD and when they were diagnosed. Given that TD can develop insidiously and may be masked by ongoing metoclopramide use, the date of discovery may be later than the date of last exposure. The adequacy of warnings regarding Reglan and TD is a central issue in settlement considerations. The FDA-approved label includes a boxed warning that clearly states the risk of TD increases with duration of treatment and total cumulative dosage, and that Reglan should be used for the shortest duration possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were prescribed Reglan for extended periods, sometimes years, despite the label limiting use to 12 weeks for gastroesophageal reflux and advising against longer-term use for diabetic gastroparesis unless unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was not adequately warned about the risk of TD or was prescribed Reglan beyond the recommended duration, this may support a claim for inadequate warnings or negligent prescribing.
Settlement-related considerations for affected patients include the severity of TD symptoms, the duration of Reglan use, the presence of other risk factors, and the impact on daily functioning. Patients who developed TD after long-term use may have stronger claims, as the label explicitly warns against prolonged treatment. The timeline between exposure and documented harm is also important: TD can appear months or years after starting Reglan, and symptoms may worsen even after discontinuation. In New York, the statute of limitations clock may start ticking when the patient first experiences symptoms that a reasonable person would associate with the medication, or when a formal diagnosis is made. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the date of last Reglan use, the date of TD diagnosis, and any evidence of inadequate warnings. The boxed warning and prescribing information provide clear documentation of the known risks, which can be used to support claims that the manufacturer failed to adequately communicate these risks to prescribers and patients.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New York, personal injury claims generally must be filed within three years of the date the injury was discovered or should have been discovered. For medical malpractice claims, the statute of limitations is typically two and a half years from the date of the alleged malpractice or from the end of continuous treatment. However, the specific timeline can vary based on when symptoms first appeared or when a diagnosis was made. It is important to consult with an attorney to determine the applicable deadline for your case.
Yes, it may still be possible to file a claim. The statute of limitations clock often starts when the injury is discovered or should have been discovered. Since TD can develop insidiously and may be masked by ongoing medication use, the date of discovery may be later than the date of last exposure. An attorney can help evaluate whether your claim falls within the applicable time frame.
Key evidence includes medical records documenting Reglan use (prescriptions, dates, dosages), a formal diagnosis of tardive dyskinesia from a qualified physician, and any documentation of inadequate warnings or prolonged use beyond FDA recommendations. The FDA boxed warning and prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) can also be used to support claims of inadequate warnings.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.